ABEONA THERAPEUTICS INC.

ABEONA THERAPEUTICS INC. (ABEO) is a publicly traded US company. Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

The company reports trailing twelve-month revenue of $0 and net loss of $17.07M.

Key metrics include a return on equity of -11.8%, a debt-to-equity ratio of 0.37.

Investors tracking ABEO can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.